Cargando…
Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma
BACKGROUND: Renal atrophy is observed in an irradiated kidney. The aim of this study was to determine dose-volume histogram parameters and other factors that predict renal atrophy after 10-fraction stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC). METHODS: A total of 14 p...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881181/ https://www.ncbi.nlm.nih.gov/pubmed/27229710 http://dx.doi.org/10.1186/s13014-016-0651-5 |
_version_ | 1782433927742357504 |
---|---|
author | Yamamoto, Takaya Kadoya, Noriyuki Takeda, Ken Matsushita, Haruo Umezawa, Rei Sato, Kiyokazu Kubozono, Masaki Ito, Kengo Ishikawa, Yojiro Kozumi, Maiko Takahashi, Noriyoshi Katagiri, Yu Onishi, Hiroshi Jingu, Keiichi |
author_facet | Yamamoto, Takaya Kadoya, Noriyuki Takeda, Ken Matsushita, Haruo Umezawa, Rei Sato, Kiyokazu Kubozono, Masaki Ito, Kengo Ishikawa, Yojiro Kozumi, Maiko Takahashi, Noriyoshi Katagiri, Yu Onishi, Hiroshi Jingu, Keiichi |
author_sort | Yamamoto, Takaya |
collection | PubMed |
description | BACKGROUND: Renal atrophy is observed in an irradiated kidney. The aim of this study was to determine dose-volume histogram parameters and other factors that predict renal atrophy after 10-fraction stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC). METHODS: A total of 14 patients (11 males, 3 females) who received SBRT for RCC at Tohoku University Hospital between April 2010 and February 2014 were analyzed. The median serum creatinine level was 1.1 mg/dl and two patients had a single kidney. Nine patients were implanted with fiducial markers. The median tumor diameter was 30 mm. SBRT was delivered at 70 Gy in 10 fractions for 7 tumors, at 60 Gy in 10 fractions for 2 tumors, and at 50 Gy in 10 fractions for 5 tumors with 6 and/or 15 MV X-ray using 5 to 8 multi-static beams. Renal atrophy was assessed using post-SBRT CT images after 12–24 months intervals. Correlations were examined by Spearman rank correlation analysis. Differences between two groups were evaluated by the Mann-Whitney test, and pairwise comparisons were made by the Wilcoxon signed-rank test. RESULTS: The median tumor volume shrunk from 14.8 cc to 10.6 cc (p = 0.12), and the median irradiated kidney volume changed from 160.4 cc to 137.1 cc (p < .01). The median peak creatinine level was 1.6 mg/dl after treatment (p < .01). Percentage volumes of the irradiated kidney receiving at least 10 Gy (V(10), p = 0.03), V(20) (p < .01), V(30)(p < .01), V(40) (p = 0.01), mean irradiated kidney dose (p < .01), and magnitude of overlap between PTV and kidney volume (p = 0.03) were significantly correlated with post-treatment irradiated kidney volume in percent, and V(20)-V(30) had strong correlation (r < −0.70, p < .01). Patients with implanted fiducial markers showed a significantly lower ratio of renal atrophy (p = 0.02). CONCLUSIONS: Significant renal atrophic change was observed. Dose distribution of SBRT at 20–30 Gy had a strong correlation with renal atrophy when irradiation was performed in 10 fractions. |
format | Online Article Text |
id | pubmed-4881181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48811812016-05-27 Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma Yamamoto, Takaya Kadoya, Noriyuki Takeda, Ken Matsushita, Haruo Umezawa, Rei Sato, Kiyokazu Kubozono, Masaki Ito, Kengo Ishikawa, Yojiro Kozumi, Maiko Takahashi, Noriyoshi Katagiri, Yu Onishi, Hiroshi Jingu, Keiichi Radiat Oncol Research BACKGROUND: Renal atrophy is observed in an irradiated kidney. The aim of this study was to determine dose-volume histogram parameters and other factors that predict renal atrophy after 10-fraction stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC). METHODS: A total of 14 patients (11 males, 3 females) who received SBRT for RCC at Tohoku University Hospital between April 2010 and February 2014 were analyzed. The median serum creatinine level was 1.1 mg/dl and two patients had a single kidney. Nine patients were implanted with fiducial markers. The median tumor diameter was 30 mm. SBRT was delivered at 70 Gy in 10 fractions for 7 tumors, at 60 Gy in 10 fractions for 2 tumors, and at 50 Gy in 10 fractions for 5 tumors with 6 and/or 15 MV X-ray using 5 to 8 multi-static beams. Renal atrophy was assessed using post-SBRT CT images after 12–24 months intervals. Correlations were examined by Spearman rank correlation analysis. Differences between two groups were evaluated by the Mann-Whitney test, and pairwise comparisons were made by the Wilcoxon signed-rank test. RESULTS: The median tumor volume shrunk from 14.8 cc to 10.6 cc (p = 0.12), and the median irradiated kidney volume changed from 160.4 cc to 137.1 cc (p < .01). The median peak creatinine level was 1.6 mg/dl after treatment (p < .01). Percentage volumes of the irradiated kidney receiving at least 10 Gy (V(10), p = 0.03), V(20) (p < .01), V(30)(p < .01), V(40) (p = 0.01), mean irradiated kidney dose (p < .01), and magnitude of overlap between PTV and kidney volume (p = 0.03) were significantly correlated with post-treatment irradiated kidney volume in percent, and V(20)-V(30) had strong correlation (r < −0.70, p < .01). Patients with implanted fiducial markers showed a significantly lower ratio of renal atrophy (p = 0.02). CONCLUSIONS: Significant renal atrophic change was observed. Dose distribution of SBRT at 20–30 Gy had a strong correlation with renal atrophy when irradiation was performed in 10 fractions. BioMed Central 2016-05-26 /pmc/articles/PMC4881181/ /pubmed/27229710 http://dx.doi.org/10.1186/s13014-016-0651-5 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Yamamoto, Takaya Kadoya, Noriyuki Takeda, Ken Matsushita, Haruo Umezawa, Rei Sato, Kiyokazu Kubozono, Masaki Ito, Kengo Ishikawa, Yojiro Kozumi, Maiko Takahashi, Noriyoshi Katagiri, Yu Onishi, Hiroshi Jingu, Keiichi Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma |
title | Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma |
title_full | Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma |
title_fullStr | Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma |
title_full_unstemmed | Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma |
title_short | Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma |
title_sort | renal atrophy after stereotactic body radiotherapy for renal cell carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881181/ https://www.ncbi.nlm.nih.gov/pubmed/27229710 http://dx.doi.org/10.1186/s13014-016-0651-5 |
work_keys_str_mv | AT yamamototakaya renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT kadoyanoriyuki renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT takedaken renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT matsushitaharuo renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT umezawarei renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT satokiyokazu renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT kubozonomasaki renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT itokengo renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT ishikawayojiro renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT kozumimaiko renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT takahashinoriyoshi renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT katagiriyu renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT onishihiroshi renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma AT jingukeiichi renalatrophyafterstereotacticbodyradiotherapyforrenalcellcarcinoma |